Urologist Brian Murray, M.D., of Capital Region Urology, a practice of St. Peter’s Health Partners Medical Associates, has published research in the peer-reviewed Journal of Comparative Effectiveness Research.
The article, titled “Cost-effectiveness of overactive bladder treatments: from the US Payer Perspective,” focuses on both pharmacologic and non-pharmacologic treatment options for overactive bladder (OAB). OnabotulinumtoxinA (BOTOX) and implantable nerve stimulation devices were among the options explored in the article.
The study is part of a limited body of research examining the cost-effectiveness of treating the chronic condition, particularly in the United States. Dr. Murray points out, expanding this type of research is key to managing population health.
From the article:
“Given the health and economic burden of OAB, understanding the cost-effectiveness of all available treatment options is critical for informing treatment decisions. Yet, to date, most economic assessments were performed outside the USA, with only a single investigation having reported a cost-comparative analysis of OAB treatments in the USA.”
Click here to read the full article.
